Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. raised its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHFree Report) by 40.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 62,160 shares of the company’s stock after acquiring an additional 18,021 shares during the period. Jupiter Asset Management Ltd.’s holdings in Deciphera Pharmaceuticals were worth $791,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Deciphera Pharmaceuticals by 23.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,127 shares of the company’s stock valued at $589,000 after purchasing an additional 8,079 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $1,167,000. Braidwell LP grew its stake in shares of Deciphera Pharmaceuticals by 12.5% in the 2nd quarter. Braidwell LP now owns 3,646,419 shares of the company’s stock valued at $51,342,000 after purchasing an additional 405,068 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Deciphera Pharmaceuticals by 6.3% in the 2nd quarter. Principal Financial Group Inc. now owns 16,567 shares of the company’s stock valued at $233,000 after purchasing an additional 983 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Deciphera Pharmaceuticals in the 2nd quarter valued at approximately $1,939,000. 70.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Jonestrading upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. HC Wainwright raised their price target on Deciphera Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $14.00 price target on shares of Deciphera Pharmaceuticals in a report on Monday, November 20th. Stifel Nicolaus raised their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Piper Sandler raised Deciphera Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $18.00 to $23.00 in a report on Monday, October 30th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Deciphera Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $22.60.

Read Our Latest Stock Analysis on DCPH

Insider Buying and Selling

In related news, EVP Matthew L. Sherman sold 2,435 shares of Deciphera Pharmaceuticals stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $14.47, for a total transaction of $35,234.45. Following the completion of the transaction, the executive vice president now directly owns 94,079 shares of the company’s stock, valued at $1,361,323.13. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.43% of the stock is currently owned by insiders.

Deciphera Pharmaceuticals Price Performance

DCPH opened at $15.73 on Monday. The business has a 50 day simple moving average of $15.06 and a 200-day simple moving average of $13.57. Deciphera Pharmaceuticals, Inc. has a 12 month low of $9.90 and a 12 month high of $17.69.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The firm had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. Deciphera Pharmaceuticals’s revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.60) earnings per share. On average, equities research analysts predict that Deciphera Pharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.

Deciphera Pharmaceuticals Profile

(Free Report)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

See Also

Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHFree Report).

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.